
ASSOCIATION BETWEEN LOSS OF Dp140 AND COGNITIVE
IMPAIRMENT IN DUCHENNE AND BECKER DYSTROPHIES Chamova T1,*, Guergueltcheva V1, Raycheva M1, Todorov T2,3,
Genova J2, Bichev S4, Bojinova V5, Mitev V3, Tournev I1,6, Todorova A2,3 *Corresponding Author: Teodora Chamova, M.D., Ph.D., Clinic of Neurology, University Hospital “Alexandrovska”,
1 Georgi Sofiiski str., Sofia 1431, Bulgaria; Tel.: +359-889802252; Fax: +359-2-9526787; E-mail: teodoratch@abv.bg page: 21
|
DISCUSSION
Dystrophinopathies provide a unique opportunity
to investigate cognitive impairment caused by mutations
in a single gene and to analyze the impact of a
dysfunctional dystrophin in the complex pathogenesis
of cognitive impairment. Among patients with dystrophinopathies,
there is a higher rate of cognitive
disorders and mental retardation than in the normally
developing population [16,17]. In the present study,
we found that the patients with DMD and IMD had
typically lower average intelligence with a mean IQ
of 86.98 ± 15.34, which is 1 SD below the population
mean. The large SD reflects the enormous cognitive
variation, found in the DMD patient group, whose IQs
varied between 53 and 124. The results are consistent
with previous studies [22,24]. Our BMD group had an
IQ of 85.62 ± 10.40, which is close to some previous
reports [18]. According to our data, there was not a
statistically significant difference between the average IQ of patients with DMD, IMD and BMD on the
one hand, but on the other hand, the percentage of
mentally retarded DMD boys was greater (15.0 vs.
7.0%). The fact that in our study the number of DMD
patients was larger than BMD patients shoud also be
taken into consideration.
In recent years, our knowledge concerning the
function of dystrophin in CNS has expanded. The
etiology of cognitive disturbances of patients with
dystrophinopathies have been widely investigated
[9-12,16,17,20,22,23]. Over the past few years, short
distal dystrophin isoforms (Dp140, Dp71) with major
cerebral expression have been discovered. Although
Dp140 function is still unclear, we found a significant
difference in cognitive performance in patients with
a presumably intact dystrophin isoform Dp140 vs.
patients in whom this isoform was predicted to be
absent in the brain, due to mutations in the regulatory
region or translation start-site. Our data showed
a significant difference in general cognitive abilities
between patients with an intact Dp140 isoform (90.31
± 12.95) and patients whose deletion was predicted to
be incompatible with the formation of an intact Dp140
(78.88 ± 13.98). Moreover, the Dp140[–] population
was found to perform more poorly on tests measuring
verbal memory, executive functions and attention
compared to the Dp140[+] population.
These data support the increasingly recognized
role of Dp140 in the cognitive functioning of the brain.
The problem with cognitive impairment seems to be
more complex. Although two of our patients were
brothers, sharing the same defect, deletion of exons
45-53 of the DMD gene and the same social background,
their IQ differed by 18 points (83 and 65).
Thus, we can suppose there are some modifying factors
that should be thoroughly investigated. This is
in contrast to the findings of Taylor et al. [20], who
described good concordance in IQ not only among
siblings but also among unrelated patients with the
same mutations.
In summary, the findings of the present study
demonstrated that the cognitive profiles of patients
with dystro-phinopathies is characterized by lower
general intelligence compared to the healthy population.
The frequency of mental retardation is higher in
patients with DMD. Defective dystrophin isoforms (in
particular Dp140) seem to be one of the major factors,
influencing the neuropsychological development and
functions in patients with DMD, IMD and BMD.
|
|
|
|



 |
Number 27 VOL. 27 (2), 2024 |
Number 27 VOL. 27 (1), 2024 |
Number 26 Number 26 VOL. 26(2), 2023 All in one |
Number 26 VOL. 26(2), 2023 |
Number 26 VOL. 26, 2023 Supplement |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|